Identifying and Validating Biomarkers to Develop Truly Disease Modifying Therapeutics for Alzheimer’s Disease

The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement!

Back for its 2nd year there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves intoblood-based biomarkers, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s including: 

  • Utilizing Animal Models & Their Translational Models 
  • Advancements in Patient Stratification & Identification 
  • Updates in Neurodegenerative Disease Modelling 
  • Presenting Biomarker Efficacy & Clinical Validation 

For the full program, download the brochure here

The Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.   

World-Class Speaker Faculty Includes:

Michael Fossel

President & Founder


Michela Gallagher

Founder & Chief Executive Officer


Christopher Winrow

Head of Translational Medicine

Cyclerion Therapeutics

Jonathan Levenson

Vice President of Translational Biology

Tiaki Therapeutics

Felix Yeh

Head of Biomarkers


Stan Chamberlain

Chief Scientific Officer

T3D Therapeutics

Mark Frasier

Co-Chief Scientific Officer

The Michael J Fox Foundation

Elizabeth Somers

Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics


Brent Vaughan

Chief Executive Officer

Cognito Therapeutics

Stefan Barghorn

Senior Principal Research Scientist Molecular & Imaging Biomarkers


Other Events in the World CNS Series: